PRA International, IntrinsiQ Research Sign Exclusive Agreement For Oncology Patient Treatment Data
PRA International (Nasdaq: PRAI - News), a leading global clinical research organization, today announced that it has entered into an exclusive licensing agreement with IntrinsiQ Research for use of the company’s Intellidose electronic medical record software used to manage oncology patients in the United States. IntrinsiQ Research collects real-time, longitudinal data on more than 45,000 patient treatments for nearly every type of cancer each month from over 600 oncology physicians. The data can be used to precisely forecast patient recruitment, thus accelerating the pace of clinical trials.
“Access to the IntrinsiQ Research data, combined with our recently announced alliance with US Oncology, reinforces our leadership position in oncology clinical research,” said Kent Thoelke, Senior Vice President, Therapeutic Expertise, at PRA. “The most critical issue today in oncology drug development is the ability to determine the available patient population for any specific tumor type. PRA is using the data from IntrinsiQ Research to accurately predict patient enrollment for clinical trials in oncology and we have already demonstrated the benefits to several sponsors by exceeding their expectations for patient recruitment timelines and budgets.”
The IntrinsiQ data includes detailed information on demographics, tumor type, stage of disease, previous treatment, current anticancer regimens, concomitant medication, laboratory measurements, scans, response data, time to progression, and other key factors. IntrinsiQ Research treatment data are regularly validated and thereby are a representative sample of oncology patients in the United States.
“IntrinsiQ’s oncology data is the established industry benchmark, in use by 90 percent of the pharmaceutical companies in the US, as well as industry analysts. This agreement with PRA allows us to extend our leadership position into the contract research space,” said Jeff Forringer, General Manager of IntrinsiQ’s pharmaceutical division. “Through the use of our treatment data, PRA will be able to help pharmaceutical companies plan more efficient oncology clinical trials. Ultimately, this will mean bringing new medicines to market faster and improving patient care.”
Dr. Monika Pietrek, Executive Vice President, Scientific & Medical Affairs at PRA, added: “One of PRA’s key growth strategies is to ’lead with science’ and this agreement with IntrinsiQ Research demonstrates our commitment to differentiate ourselves with our therapeutic expertise.”
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.